Efficacy of Selpercatinib Beyond NSCLC Progression
Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.
Allergy & Immunology